“We’ve had changes in our EVAR [endovascular aneurysm repair] devices, we’ve had changes in our CLTI [chronic limb-threatening ischaemia], lower extremity, PAD [peripheral arterial disease] intervention devices, so it only makes sense that we’re going to have changes in our carotid stenting devices as well.”
So says Patrick Muck (Good Samaritan Hospital, Cincinnati, USA), co-lead investigator in the CGUARDIANS II and III trials investigating use of the CGuard Prime 80cm carotid stent for use in transcarotid artery revascularisation (TCAR) procedures, who tells Vascular News on the fringes of the 2026 Vascular Annual Meeting (VAM; 10–13 June, Boston, USA) how innovation is driving change in carotid artery stenting.
